A systematic review on drugs absorption modifications after eradication in Helicobacter pylori positive patients undergoing replacement therapy

Giulia Fiorini, John Martin Bland, Elizabeth Hughes, Valentina Castelli, Dino Vaira

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Background & Aims: Helicobacter pylori (H. pylori) infection has been suggested as a cause of impaired drug absorption. This infection leads to alteration of the gastric acid secretion that may change the conformational characteristics of drugs and their intestinal absorption leading to uncertainties about the dose to administer and the therapeutic results. A systematic review was undertaken to clarify the implications of drug absorption during the administration of replacement therapies. Methods: Electronic databases such as MEDLINE/Pubmed, EMBASE and The Cochrane Library [which includes Cochrane Database of Systematic Review (CDSR), the Cochrane Central Register of Controlled Trials (CENTRAL), the Database of Abstract of Reviews of Effect (DARE)] were searched. Grey literature databases (e.g. the International clinical trials registry platform, Trials Register, Clinical Trials.gov, Controlled Trials and TrialsCentral), Theses database, Government publication and LILACS database were also searched. No language restriction was applied. Results: Infection and altered drug absorption were evaluated in patients under replacement therapies with iron, thyroxin and L-dopa. In all, seven studies included an improvement in drug absorption after eradication and an existing inverse correlation between the grade of gastric inflammation and indices of drug absorption were noticed. Conclusion: This systematic review confirmed the presence of an interaction between infection and drug absorption of orally administered replacement therapies. Gastric acid reduction and subsequent alteration of drug composition seem to lead this mechanism. Clinicians should be aware of this possible interaction when starting a replacement therapy in patients and when evaluating poor clinical response.

LanguageEnglish
Pages95-100
Number of pages6
JournalJournal of Gastrointestinal and Liver Diseases
Volume24
Issue number1
DOIs
Publication statusPublished - Mar 2015
Externally publishedYes

Fingerprint

Helicobacter pylori
Databases
Pharmaceutical Preparations
Gastric Acid
Therapeutics
Government Publications
Infection
Clinical Trials
Intestinal Absorption
Levodopa
Helicobacter Infections
Thyroxine
PubMed
MEDLINE
Libraries
Uncertainty
Registries
Stomach
Language
Iron

Cite this

Fiorini, Giulia ; Bland, John Martin ; Hughes, Elizabeth ; Castelli, Valentina ; Vaira, Dino. / A systematic review on drugs absorption modifications after eradication in Helicobacter pylori positive patients undergoing replacement therapy. In: Journal of Gastrointestinal and Liver Diseases. 2015 ; Vol. 24, No. 1. pp. 95-100.
@article{4519569e1c6f45148c8414e1620ec9b8,
title = "A systematic review on drugs absorption modifications after eradication in Helicobacter pylori positive patients undergoing replacement therapy",
abstract = "Background & Aims: Helicobacter pylori (H. pylori) infection has been suggested as a cause of impaired drug absorption. This infection leads to alteration of the gastric acid secretion that may change the conformational characteristics of drugs and their intestinal absorption leading to uncertainties about the dose to administer and the therapeutic results. A systematic review was undertaken to clarify the implications of drug absorption during the administration of replacement therapies. Methods: Electronic databases such as MEDLINE/Pubmed, EMBASE and The Cochrane Library [which includes Cochrane Database of Systematic Review (CDSR), the Cochrane Central Register of Controlled Trials (CENTRAL), the Database of Abstract of Reviews of Effect (DARE)] were searched. Grey literature databases (e.g. the International clinical trials registry platform, Trials Register, Clinical Trials.gov, Controlled Trials and TrialsCentral), Theses database, Government publication and LILACS database were also searched. No language restriction was applied. Results: Infection and altered drug absorption were evaluated in patients under replacement therapies with iron, thyroxin and L-dopa. In all, seven studies included an improvement in drug absorption after eradication and an existing inverse correlation between the grade of gastric inflammation and indices of drug absorption were noticed. Conclusion: This systematic review confirmed the presence of an interaction between infection and drug absorption of orally administered replacement therapies. Gastric acid reduction and subsequent alteration of drug composition seem to lead this mechanism. Clinicians should be aware of this possible interaction when starting a replacement therapy in patients and when evaluating poor clinical response.",
keywords = "Absorption, Helicobacter pylori, Replacement therapy",
author = "Giulia Fiorini and Bland, {John Martin} and Elizabeth Hughes and Valentina Castelli and Dino Vaira",
year = "2015",
month = "3",
doi = "10.15403/jgld.2014.1121.fio",
language = "English",
volume = "24",
pages = "95--100",
journal = "Journal of Gastrointestinal and Liver Diseases",
issn = "1841-8724",
publisher = "Romanian Society of Gastroenterology",
number = "1",

}

A systematic review on drugs absorption modifications after eradication in Helicobacter pylori positive patients undergoing replacement therapy. / Fiorini, Giulia; Bland, John Martin; Hughes, Elizabeth; Castelli, Valentina; Vaira, Dino.

In: Journal of Gastrointestinal and Liver Diseases, Vol. 24, No. 1, 03.2015, p. 95-100.

Research output: Contribution to journalReview article

TY - JOUR

T1 - A systematic review on drugs absorption modifications after eradication in Helicobacter pylori positive patients undergoing replacement therapy

AU - Fiorini, Giulia

AU - Bland, John Martin

AU - Hughes, Elizabeth

AU - Castelli, Valentina

AU - Vaira, Dino

PY - 2015/3

Y1 - 2015/3

N2 - Background & Aims: Helicobacter pylori (H. pylori) infection has been suggested as a cause of impaired drug absorption. This infection leads to alteration of the gastric acid secretion that may change the conformational characteristics of drugs and their intestinal absorption leading to uncertainties about the dose to administer and the therapeutic results. A systematic review was undertaken to clarify the implications of drug absorption during the administration of replacement therapies. Methods: Electronic databases such as MEDLINE/Pubmed, EMBASE and The Cochrane Library [which includes Cochrane Database of Systematic Review (CDSR), the Cochrane Central Register of Controlled Trials (CENTRAL), the Database of Abstract of Reviews of Effect (DARE)] were searched. Grey literature databases (e.g. the International clinical trials registry platform, Trials Register, Clinical Trials.gov, Controlled Trials and TrialsCentral), Theses database, Government publication and LILACS database were also searched. No language restriction was applied. Results: Infection and altered drug absorption were evaluated in patients under replacement therapies with iron, thyroxin and L-dopa. In all, seven studies included an improvement in drug absorption after eradication and an existing inverse correlation between the grade of gastric inflammation and indices of drug absorption were noticed. Conclusion: This systematic review confirmed the presence of an interaction between infection and drug absorption of orally administered replacement therapies. Gastric acid reduction and subsequent alteration of drug composition seem to lead this mechanism. Clinicians should be aware of this possible interaction when starting a replacement therapy in patients and when evaluating poor clinical response.

AB - Background & Aims: Helicobacter pylori (H. pylori) infection has been suggested as a cause of impaired drug absorption. This infection leads to alteration of the gastric acid secretion that may change the conformational characteristics of drugs and their intestinal absorption leading to uncertainties about the dose to administer and the therapeutic results. A systematic review was undertaken to clarify the implications of drug absorption during the administration of replacement therapies. Methods: Electronic databases such as MEDLINE/Pubmed, EMBASE and The Cochrane Library [which includes Cochrane Database of Systematic Review (CDSR), the Cochrane Central Register of Controlled Trials (CENTRAL), the Database of Abstract of Reviews of Effect (DARE)] were searched. Grey literature databases (e.g. the International clinical trials registry platform, Trials Register, Clinical Trials.gov, Controlled Trials and TrialsCentral), Theses database, Government publication and LILACS database were also searched. No language restriction was applied. Results: Infection and altered drug absorption were evaluated in patients under replacement therapies with iron, thyroxin and L-dopa. In all, seven studies included an improvement in drug absorption after eradication and an existing inverse correlation between the grade of gastric inflammation and indices of drug absorption were noticed. Conclusion: This systematic review confirmed the presence of an interaction between infection and drug absorption of orally administered replacement therapies. Gastric acid reduction and subsequent alteration of drug composition seem to lead this mechanism. Clinicians should be aware of this possible interaction when starting a replacement therapy in patients and when evaluating poor clinical response.

KW - Absorption

KW - Helicobacter pylori

KW - Replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=84924118923&partnerID=8YFLogxK

U2 - 10.15403/jgld.2014.1121.fio

DO - 10.15403/jgld.2014.1121.fio

M3 - Review article

VL - 24

SP - 95

EP - 100

JO - Journal of Gastrointestinal and Liver Diseases

T2 - Journal of Gastrointestinal and Liver Diseases

JF - Journal of Gastrointestinal and Liver Diseases

SN - 1841-8724

IS - 1

ER -